Press Release

View printer-friendly version
« Back
Voyager Therapeutics to Attend Upcoming Investor Conferences

CAMBRIDGE, Mass., June 02, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases, today announced that Steven Paul, M.D., president and chief executive officer, will present at the following investor conferences:

  • Jefferies 2017 Healthcare Conference, New York City
    Date: Friday, June 9, 2017
    Time: 10:30 a.m. EDT

  • Goldman Sachs Healthcare Conference, Rancho Palos Verdes, CA
    Date: Wednesday, June 14, 2017
    Time: 5:40 p.m. EDT (2:40 p.m. PDT)

Live-streaming webcasts of these presentations can be accessed through the Investors & Media section of Voyager’s website at  The webcast will be archived for 30 days after the live event concludes.

About Voyager Therapeutics

Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe neurological diseases.  Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques.  The company’s pipeline focuses on severe neurological diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of ALS, Huntington’s disease, Friedreich’s ataxia, frontotemporal dementia, Alzheimer’s disease and severe, chronic pain.  Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School.  Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts.  For more information, please visit  Follow Voyager on LinkedIn.

Investor Relations:   
Matt Osborne
Head of Investor Relations & Corporate Communications

Katie Engleman
Pure Communications, Inc.

Primary Logo

Voyager Therapeutics